High Throughput Screening

高通量筛选核心(HTS)通过以下方式支持基础和转化型生物医学研究 设计、优化和运行高通量分析，为癌症提供潜在的治疗方法。这是 通过将机器人、检测系统、化学/生物物库和数据管理与 在流程中的每一步优化技术和成果方面的专业知识。HTS提供Holden 综合性癌症中心(HCCC)成员，拥有可扩展的早期、临床前治疗开发， 包括小分子疗法、抗体、siRNA、反义寡核苷酸和其他生物制品 包括患者衍生的细胞疗法。它还支持高通量筛选，用于探索 癌症生物学。HTS配备了在96井、384井和1536井进行高通量筛选的能力 格式，具有平板阅读器检测(Perkin-Elmer enVision)，使用吸光度、荧光和 发光，包括先进的FRET和BRET技术。HTS还可以进行高含量筛选 (Perkin-Elmer opetta共焦成像系统)以检测和量化表型变化，即细胞 分化、细胞迁移、突起生长和靶运输或靶的荧光强度 蛋白质表达、转录因子或信号通路分析。

The High Throughput Screening Core (HTS) supports basic and translational biomedical research by designing, optimizing, and running high throughput assays that deliver potential therapeutics for cancer. This is done by integrating robotics, detection systems, chemical /biologics libraries and data management with expertise in optimizing technologies and outcomes along each step in the process. HTS provides Holden Comprehensive Cancer Center (HCCC) members with scalable early, pre-clinical development of therapeutics, including small molecule therapeutics, antibodies, siRNAs, antisense oligonucleotides and other biologics including patient-derived cell therapeutics. It also supports high throughput screening for studies exploring the biology of cancer. The HTS is equipped to perform high-throughput screening in 96-, 384- and 1536- well formats, with plate reader detection (Perkin-Elmer EnVision) using absorbance, fluorescence and luminescence, including advanced FRET and BRET techniques. HTS can also perform high content screening (HCS, Perkin-Elmer Operetta Confocal Imaging System) to detect and quantify phenotypic changes, i.e., cell differentiation, cell migration, neurite outgrowth, and target trafficking or by fluorescence intensities for target protein expression, transcription factor or signaling pathway analysis.